Your browser doesn't support javascript.
loading
Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
Bachanova, Veronika; Burns, Linda J; Ahn, Kwang Woo; Laport, Ginna G; Akpek, Görgün; Kharfan-Dabaja, Mohamed A; Nishihori, Taiga; Agura, Edward; Armand, Philippe; Jaglowski, Samantha M; Cairo, Mitchell S; Cashen, Amanda F; Cohen, Jonathon B; D'Souza, Anita; Freytes, César O; Gale, Robert Peter; Ganguly, Siddhartha; Ghosh, Nilanjan; Holmberg, Leona A; Inwards, David J; Kanate, Abraham S; Lazarus, Hillard M; Malone, Adriana K; Munker, Reinhold; Mussetti, Alberto; Norkin, Maxim; Prestidge, Tim D; Rowe, Jacob M; Satwani, Prakash; Siddiqi, Tanya; Stiff, Patrick J; William, Basem M; Wirk, Baldeep; Maloney, David G; Smith, Sonali M; Sureda, Anna M; Carreras, Jeanette; Hamadani, Mehdi.
Afiliação
  • Bachanova V; Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, Minnesota. Electronic address: bach0173@umn.edu.
  • Burns LJ; Health Services Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
  • Ahn KW; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Laport GG; Division of Bone Marrow Transplant, Stanford Hospital and Clinics, Stanford, California.
  • Akpek G; Stem Cell Transplantation and Cellular Therapy Program, Banner MD Anderson Cancer Center, Gilbert, Arizona.
  • Kharfan-Dabaja MA; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Nishihori T; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Agura E; Blood and Marrow Transplant Services, Baylor University Medical Center, Dallas, Texas.
  • Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jaglowski SM; Division of Hematology, The Ohio State University Medical Center, Columbus, Ohio.
  • Cairo MS; Department of Pediatrics, New York Medical College, Valhalla, New York.
  • Cashen AF; Department of BMT/Oncology, Barnes Jewish Hospital, St. Louis, Missouri.
  • Cohen JB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
  • D'Souza A; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Freytes CO; South Texas Veterans Health Care System and University of Texas Health Science Center San Antonio, San Antonio, Texas.
  • Gale RP; Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
  • Ganguly S; Blood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.
  • Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina.
  • Holmberg LA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Inwards DJ; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
  • Kanate AS; Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia.
  • Lazarus HM; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio.
  • Malone AK; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Munker R; Section of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, Louisiana.
  • Mussetti A; S.C. Ematologia e Trapianto Midollo Osseo, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy; Università degli Studi di Milano, Milan, Italy.
  • Norkin M; Division of Hematology/Oncology, University Florida College of Medicine, Gainesville, Florida.
  • Prestidge TD; Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.
  • Rowe JM; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Satwani P; Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, New York.
  • Siddiqi T; Department of Hematology Oncology, City of Hope National Medical Center, Duarte, California.
  • Stiff PJ; Department of Hematology/Oncology, Loyola University Medical Center, Chicago, Illinois.
  • William BM; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio.
  • Wirk B; Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
  • Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Smith SM; Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois.
  • Sureda AM; Servei d'Hematologia, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Secretary, European Group for Blood and Marrow Transplantation.
  • Carreras J; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Hamadani M; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Biol Blood Marrow Transplant ; 21(9): 1605-11, 2015 Sep.
Article em En | MEDLINE | ID: mdl-25983043
ABSTRACT
Assessment with (18)F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Transplante de Células-Tronco Hematopoéticas / Fluordesoxiglucose F18 / Tomografia por Emissão de Pósitrons Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Transplante de Células-Tronco Hematopoéticas / Fluordesoxiglucose F18 / Tomografia por Emissão de Pósitrons Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article